The COVID-19 Crisis Is A Signal – Need To ‘Reset’ Global Health Financing 27/11/2020 Ilona Kickbusch We are kicking off our expanded new series of opinion pieces, with Ilona Kickbusch’s reflections on last week’s G-20 and the mission of COVID vaccine distribution – what she describes as the most “defining global challenge” of 2021. We invite contributions from health policy leaders, influencers and practitioners who wish to speak out on issues […] Continue reading -> Africa’s COVID Vaccine Roll-Out Depends On Restoring Other Vaccination Programs 27/11/2020 Paul Adepoju Africa’s COVID-19 rollout is anticipated for Spring 2021, despite the continent’s low vaccine preparedness, multiple health leaders in Africa have said, as policy advisory groups flag the importance that other successful immunization campaigns will have on COVID recovery. At a press briefing on Thursday, Dr. John Nkengasong, Director of Africa CDC, said: “Africa may have […] Continue reading -> AstraZeneca Vaccine Most Attractive Option For Africa, Says WHO – Astra Zeneca CEO Says Company Will Run New Trial To Test More Efficient Dose 26/11/2020 Maina Waruru & Elaine Ruth Fletcher Nairobi. Africa’s limited cold-chain capacity will constrain the continent’s ability to take up the more cutting-edge Pfizer and Moderna vaccines that are likely to win approval first from regulatory authorities, said WHO’s African Regional Director Dr Matshidiso Moeti on Thursday. Those same constraints make the AstraZeneca (AZD1222) vaccine the most attractive option, despite its lower […] Continue reading -> Philanthropy Alone Will Not Ensure Global Access To COVID-19 Vaccines – South Africa’s Take 25/11/2020 Kerry Cullinan & Elaine Ruth Fletcher South Africa is campaigning for the World Trade Organization (WTO) to waiver intellectual property rights on all products related to COVID-19 for the duration of the pandemic. Mustaqeem De Gama, Counsellor at the South African Permanent Mission in Geneva, is leading the campaign. Kerry Cullinan and Elaine Fletcher spoke to him about the reasons why […] Continue reading -> Major New Clinical Trial Launched Across 13 African Countries To Test Treatments For Mild COVID-19 Cases 24/11/2020 Elaine Ruth Fletcher Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading -> AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Africa’s COVID Vaccine Roll-Out Depends On Restoring Other Vaccination Programs 27/11/2020 Paul Adepoju Africa’s COVID-19 rollout is anticipated for Spring 2021, despite the continent’s low vaccine preparedness, multiple health leaders in Africa have said, as policy advisory groups flag the importance that other successful immunization campaigns will have on COVID recovery. At a press briefing on Thursday, Dr. John Nkengasong, Director of Africa CDC, said: “Africa may have […] Continue reading -> AstraZeneca Vaccine Most Attractive Option For Africa, Says WHO – Astra Zeneca CEO Says Company Will Run New Trial To Test More Efficient Dose 26/11/2020 Maina Waruru & Elaine Ruth Fletcher Nairobi. Africa’s limited cold-chain capacity will constrain the continent’s ability to take up the more cutting-edge Pfizer and Moderna vaccines that are likely to win approval first from regulatory authorities, said WHO’s African Regional Director Dr Matshidiso Moeti on Thursday. Those same constraints make the AstraZeneca (AZD1222) vaccine the most attractive option, despite its lower […] Continue reading -> Philanthropy Alone Will Not Ensure Global Access To COVID-19 Vaccines – South Africa’s Take 25/11/2020 Kerry Cullinan & Elaine Ruth Fletcher South Africa is campaigning for the World Trade Organization (WTO) to waiver intellectual property rights on all products related to COVID-19 for the duration of the pandemic. Mustaqeem De Gama, Counsellor at the South African Permanent Mission in Geneva, is leading the campaign. Kerry Cullinan and Elaine Fletcher spoke to him about the reasons why […] Continue reading -> Major New Clinical Trial Launched Across 13 African Countries To Test Treatments For Mild COVID-19 Cases 24/11/2020 Elaine Ruth Fletcher Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading -> AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
AstraZeneca Vaccine Most Attractive Option For Africa, Says WHO – Astra Zeneca CEO Says Company Will Run New Trial To Test More Efficient Dose 26/11/2020 Maina Waruru & Elaine Ruth Fletcher Nairobi. Africa’s limited cold-chain capacity will constrain the continent’s ability to take up the more cutting-edge Pfizer and Moderna vaccines that are likely to win approval first from regulatory authorities, said WHO’s African Regional Director Dr Matshidiso Moeti on Thursday. Those same constraints make the AstraZeneca (AZD1222) vaccine the most attractive option, despite its lower […] Continue reading -> Philanthropy Alone Will Not Ensure Global Access To COVID-19 Vaccines – South Africa’s Take 25/11/2020 Kerry Cullinan & Elaine Ruth Fletcher South Africa is campaigning for the World Trade Organization (WTO) to waiver intellectual property rights on all products related to COVID-19 for the duration of the pandemic. Mustaqeem De Gama, Counsellor at the South African Permanent Mission in Geneva, is leading the campaign. Kerry Cullinan and Elaine Fletcher spoke to him about the reasons why […] Continue reading -> Major New Clinical Trial Launched Across 13 African Countries To Test Treatments For Mild COVID-19 Cases 24/11/2020 Elaine Ruth Fletcher Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading -> AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Philanthropy Alone Will Not Ensure Global Access To COVID-19 Vaccines – South Africa’s Take 25/11/2020 Kerry Cullinan & Elaine Ruth Fletcher South Africa is campaigning for the World Trade Organization (WTO) to waiver intellectual property rights on all products related to COVID-19 for the duration of the pandemic. Mustaqeem De Gama, Counsellor at the South African Permanent Mission in Geneva, is leading the campaign. Kerry Cullinan and Elaine Fletcher spoke to him about the reasons why […] Continue reading -> Major New Clinical Trial Launched Across 13 African Countries To Test Treatments For Mild COVID-19 Cases 24/11/2020 Elaine Ruth Fletcher Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading -> AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Major New Clinical Trial Launched Across 13 African Countries To Test Treatments For Mild COVID-19 Cases 24/11/2020 Elaine Ruth Fletcher Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading -> AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
AstraZeneca Breakthrough Heightens Competition Between Two Different World Views On Vaccine Procurement & Distribution 23/11/2020 Elaine Ruth Fletcher, Menaka Rao & Kerry Cullinan The vaccine zero hour is approaching. As Norway’s Minister of International Development Dag Ulstein and South Africa’s Minister of Health Zweili Mkhize made yet another urgent plea Monday for some US$4.3 billion right now and another $US23.9 billion in 2021 to massively roll out new COVID19 vaccines, drugs and tests that are now coming on […] Continue reading -> AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
AstraZeneca’s COVID-19 Vaccine Candidate Can Prevent 90% Of Infections – Company Unveils Interim Results 23/11/2020 Madeleine Hoecklin & Elaine Ruth Fletcher AstraZeneca, the pharma firm developing a COVID-19 vaccine in collaboration with researchers at Oxford University, announced that its Phase 3 clinical trials had resulted in a 90% efficacy rate for one dosing regime, in interim results released on Monday. The AstraZeneca breakthrough is significant because the vaccine, based on a known vaccine delivery technology, is […] Continue reading -> Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Regeneron Antibody Treatment Granted Emergency Authorization By FDA 23/11/2020 Madeleine Hoecklin The US Food and Drug Administration (FDA) authorised an experimental antibody cocktail produced by Regeneron for emergency use on Saturday. The treatment, consisting of the two antibodies casirivimab and imdevimab, will be limited to patients aged 12 and over with positive SARS-CoV2 test results and at risk of developing severe COVID-19. Clinical trial results showed […] Continue reading -> A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
A New Era In The Fight Against Antimicrobial Resistance – Can We Revert The Silent Tsunami? 20/11/2020 Neda Milevska This week is World Antimicrobial Awareness Week, marking the fight against the silent and rising global threat of antimicrobial-resistant superbugs. Can patients be part of the solution? This week is the World Antimicrobial Awareness Week (WAAW) when we turn the world’s attention to the growing problem of drug resistant diseases – caused by bacteria, viruses […] Continue reading -> WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Recommends Against Remdesivir Use – ‘No Evidence’ It Improves Patient Outcomes 20/11/2020 J Hacker WHO on Friday issued formal guidelines recommending against the use of remdesivir for COVID-19 patients, based on a lack of evidence that the antiviral drug, developed by Gilead, significantly improves patient outcomes. The recommendation followed publication of trial results on the drug in the The BMJ involving more than 7,000 patients who had been hospitalized […] Continue reading -> Posts navigation Older postsNewer posts